Aadel Chaudhuri, MD, PhD

Aadel Chaudhuri, MD, PhD, is a physician-scientist and Assistant Professor of Radiation Oncology, Genetics, Biomedical Engineering, and Computer Science at the Washington University in St. Louis. He is also leader of the Liquid Biopsy Working Group at the Washington University Siteman Cancer Center. He additionally serves as Co-Chair of the Liquid Biopsy Interest Group within the National Institutes of Health.

Dr. Chaudhuri completed his MD at Stanford, PhD at Caltech, and BS degrees in Biology and Computer Science at MIT where he was also a Goldwater Scholar. He completed his PhD in Biology under the mentorship of Nobel Laureate David Baltimore focusing on microRNAs in cancer, and his residency at Stanford University, where he did postdoctoral work with National Academy of Medicine member Maximilian Diehn demonstrating that circulating tumor DNA serves as a powerful biomarker for molecular residual disease (MRD) after curative-intent localized lung cancer treatment. Dr. Chaudhuri has been awarded the Roentgen Research Award from the Radiological Society of North America, the Michael Fry Award by the Radiation Research Society, and is also a V Foundation V Scholar. Dr. Chaudhuri’s laboratory at Washington University focuses on the development and application of liquid biopsy cancer diagnostic technologies with the goal of more precisely personalizing solid tumor malignancy treatment. His laboratory is funded by the National Institutes of Health, the V Foundation, the Cancer Research Foundation, the Children’s Discovery Institute, the Children’s Tumor Foundation, the Alvin Siteman Cancer Research Fund, and the Melanoma Research Alliance.

Disclosures:

• Employment: Mayo Clinic:Associate Professor:Employee
• Compensation: Roche: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Honoraria, Travel Expenses, Compensation Payment-End Date: Present ;Tempus Labs: Consultant, Grant Research Funding, Compensation Payment-End Date: Present ;Geneoscopy: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Remuneration Other-End Date: Present ;Illumina: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Compensation Payment-End Date: Present ;Daiichi Sankyo: Advisory Board, Advisory
• Ownership: Geneoscopy:Stock Options;Droplet Biosciences:Ownership Equity;LiquidCell Dx Inc.:Ownership Equity;Patent filings related to cancer biomarkers:Copyright
• Leadership: Translational Lung Cancer Research:Editorial Board;Molecular Diagnosis & Therapy:Editorial Board;NIH Liquid Biopsy Interest Group:Co-Chair;Siteman Cancer Center ctDNA Working Group:Leader;NSCLC Multidisciplinary Advisory Council:Member of the advisory council;PLOS Medicine:Editorial Board;AI in Precision Oncology:Editorial Board;Mayo Clinic Department of Radiation Oncology:Vice Chair of Translational Research;Mayo Clinic Comprehensive Cancer Center:Co-Director of the Precision Genomics Office;Ma